津药药业：公司及子公司产品拟中选国家组织集采药品协议期满品种接续采购

Core Viewpoint - The company and its subsidiaries participated in the national organized procurement for drugs, with some products expected to be selected in the follow-up procurement, indicating a strategic move to secure market share in a competitive environment [1] Group 1: Financial Impact - The total expected sales revenue from the selected drugs for the year 2024 is RMB 323 million, accounting for 10.03% of the company's revenue during the same period [1] - The projected sales revenue for the first three quarters of 2025 is RMB 250 million, representing 11.20% of the company's revenue for that timeframe [1]